On September 11, 2024, Paul Diaz, President and Chief Executive Officer of Myriad Genetics Inc (NASDAQ:MYGN), sold 15,000 shares of the company at a price of $26.72 per share. The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 977,378 shares of Myriad Genetics Inc.

Myriad Genetics Inc (NASDAQ:MYGN) is a company that focuses on the discovery and commercialization of novel molecular diagnostic tests. These tests are designed to assess an individual's risk of developing a disease, aid in diagnosis, assess risk of disease progression and recurrence, and guide treatment decisions across six medical specialties where genetic insights can significantly improve patient care.

Over the past year, Paul Diaz has sold a total of 242,844 shares of Myriad Genetics Inc and has not made any purchases of the stock. The insider transaction history for Myriad Genetics Inc shows a pattern of 11 insider sells and no insider buys over the same timeframe.

On the valuation front, Myriad Genetics Inc's shares were trading at $26.72 on the day of the sale, giving the company a market cap of approximately $2.40 billion. According to the GF Value, which is an intrinsic value estimate from GuruFocus, the stock is currently modestly overvalued with a price-to-GF-Value ratio of 1.14. The GF Value is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the companys past returns and growth, and future business performance estimates from analysts.

This insider sale may be of interest to investors tracking insider behaviors and company valuation metrics to inform their investment decisions in the biotechnology and diagnostics sectors.